scholarly journals Persistence and gender differences in protection against severe fever with thrombocytopaenia syndrome virus with natural infection: a 4-year follow-up and mathematical prediction study

2019 ◽  
Vol 147 ◽  
Author(s):  
R. Qi ◽  
Y.T. Huang ◽  
X.J. Yu
Keyword(s):  
Infectious Disease ◽  
Gender Differences ◽  
Natural Infection ◽  
Geometric Mean ◽  
Case Fatality ◽  
Immune Protection ◽  
Neutralising Antibodies ◽  
And Gender ◽  
Severe Fever

SummarySevere fever with thrombocytopaenia syndrome (SFTS) is an emerging infectious disease discovered in 2010 and has a case fatality as high as 30%. We intended to study the immune protection conferred by SFTS with natural infection. We collected and analysed 4-year follow-up data to study the characteristics of neutralising antibodies against SFTS virus (SFTSV). The 50% plaque reduction neutralisation test was used for the detection of neutralising antibodies against SFTSV. Geometric mean titres (GMTs) and proportions of patients with a protective titre were analysed, and the persistence of protection was predicted. The titre of antibodies declined yearly in the 4-year study period. Approximately 3 months after infection, the GMT was 143 (95% confidence interval (CI): 89–231), and 100% of patients had a protective titre. In the fourth year, the GMT declined to 53 (95% CI: 37–76), and 95% of patients had a protective titre. The titre was higher in females than in males. On average, the protection offered by neutralising antibodies against SFTSV could last as long as 9 years. The durations of protection were different for different initial titres. The characteristics of neutralising antibodies can be used as a reference for the vaccination doses and schedules of forthcoming vaccines.

Age and gender differences in incidence and case fatality trends for myocardial infarction: a 30-year follow-up. The Tromsø Study

2011 ◽  
Vol 19 (5) ◽  
pp. 927-934 ◽  
Author(s):  
Jan Mannsverk ◽  
Tom Wilsgaard ◽  
Inger Njølstad ◽  
Laila Arnesdatter Hopstock ◽  
Maja-Lisa Løchen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Gender Differences ◽  
Case Fatality ◽  
Age And Gender ◽  
Age And Gender Differences ◽  
And Gender

Longitudinal follow-up of the intrusiveness of the infertility experience: predictors and gender differences

2010 ◽  
Vol 94 (4) ◽  
pp. S65
Author(s):  
U.E. Van den Broeck ◽  
L. Pasch ◽  
P. Katz ◽  
S. Millstein ◽  
T. D'Hooghe ◽  
...  
Keyword(s):  
Gender Differences ◽  
And Gender

scholarly journals Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial

2022 ◽  
Author(s):  
Krishna Mohan Vadrevu ◽  
Brunda Ganneru ◽  
Siddharth Reddy ◽  
Harsh Jogdand ◽  
Raju Dugyala ◽  
...  
Keyword(s):  
Placebo Group ◽  
Booster Dose ◽  
Natural Infection ◽  
Geometric Mean ◽  
Booster Vaccination ◽  
Secondary Outcome ◽  
Effector Memory ◽  
Cell Mediated Immunity ◽  
Phase 2 ◽  
Neutralising Antibodies

Background: Neutralising antibody responses to SARS-CoV-2 vaccines have been reported to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We assessed the immunogenicity and safety of a booster dose of BBV152 administered 6 months after the second of a two-dose primary vaccination series. Methods: In an ongoing phase 2 trial (ClinicalTrials.gov: NCT04471519) the protocol was amended after six months to re-consent and randomise 184 previously vaccinated participants to receive a third dose of vaccine or placebo on Day 215. The primary outcome was to measure neutralising antibody titres by plaque-reduction neutralisation test (PRNT50) four weeks after the booster; safety as serious adverse events (SAE) was the key secondary outcome. Findings: Four weeks after a second BBV152 vaccination geometric mean titres (GMTs) of neutralising antibodies were 197.0 PRNT50 (95% CI: 155.6,249.4); this level declined to 23.9 PRNT50 (14.0,40.6) six months later, with a seroconversion rate of 75.4% (95% CI: 68.4,81.6). Four weeks after booster vaccination the GMT increased on Day 243 to 746.6 PRNT50 (514.9,1081) compared with 100.7 PRNT50 (43.6,232.6) in the placebo group. Corresponding seroconversion rates were 98.7% (92.8,99.9) and 79.8% (69.6,87.8). Increased titres in the placebo group were attributed to natural infection as the study was conducted during the second wave of COVID-19 in India. PRNT50 titres against the SARS-CoV-2 variants increased Alpha (32.6 fold), Beta (161.0 fold), Delta (264.7 fold), and Delta plus (174.2 fold) after the booster vaccination. We found that vaccine induces both memory B and T cells with a distinct AIM+ specific CD4+T central and effector memory phenotype, including CD8+ TEMRA phenotype. Reactogenicity after vaccine and placebo was minimal and comparable, and no SAEs were reported. Interpretation: Six months after a two dose BBV152 vaccination series cell mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta and Delta plus) persisted above baseline, although the magnitude of the responses had declined. Neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased 19 to 97 fold after a third vaccination. Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections.

A 25-year follow-up of patients admitted to methadone treatment for the first time: Mortality and gender differences

2011 ◽  
Vol 36 (12) ◽  
pp. 1184-1190 ◽  
Author(s):  
Luis Jimenez-Treviño ◽  
Pilar A. Saiz ◽  
M. Paz García-Portilla ◽  
Eva M. Díaz-Mesa ◽  
Fernando Sánchez-Lasheras ◽  
...  
Keyword(s):  
Gender Differences ◽  
Methadone Treatment ◽  
And Gender ◽  
First Time

scholarly journals Cohort profile: follow-up of a Berlin Aging Study II (BASE-II) subsample as part of the GendAge study

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e045576
Author(s):  
Ilja Demuth ◽  
Verena Banszerus ◽  
Johanna Drewelies ◽  
Sandra Düzel ◽  
Ute Seeland ◽  
...  
Keyword(s):  
Gender Differences ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Sex And Gender ◽  
Ventricular Ejection Fraction ◽  
Intermediate Phenotypes ◽  
Aging Study ◽  
And Gender ◽  
Sex And Gender Differences

PurposeThe study ‘Sex- and gender-sensitive prevention of cardiovascular and metabolic disease in older adults in Germany’, the GendAge study, focuses on major risk factors for cardiovascular and metabolic diseases and on the development of major outcomes from intermediate phenotypes in the context of sex and gender differences. It is based on a follow-up examination of a subsample (older group) of the Berlin Aging Study II (BASE-II).ParticipantsThe GendAge study assessments took place between 22 June 2018 and 10 March 2020. A total of 1100 participants (older BASE-II subsample, aged ≥65 years) with baseline data assessed at least by one of the BASE-II partner sites were investigated in the follow-up. These participants had a mean age of 75.6 years (SD ±3.8), with a mean follow-up at 7.4 years (SD ±1.5).Findings to dateData from different domains such as internal medicine, geriatrics, immunology and psychology were collected, with a focus on cardiometabolic diseases and in the context of sex and gender differences. Diabetes mellitus type 2 was reported by 15.6% and 8.6% of men and women, respectively. In contrast, this disease was diagnosed in 20.7% of men and 13.3% of women, indicating that a substantial proportion of almost 30% was unaware of the disease. Echocardiography revealed that left ventricular ejection fraction was higher in women than in men, in agreement with previous reports.Future plansA gender questionnaire assessing sociocultural aspects implemented as part of the follow-up described here will allow to calculate a gender score and its evaluation based on the newly collected data. At the same time, the other BASE-II research foci established over the past 10 years will be continued and strengthened by the BASE-II transition into a longitudinal study with follow-up data on the older subsample.Trial registration numberDRKS00016157.

A Follow-Up Study of Ethnic and Gender Differences in Cardiac Rehabilitation

1996 ◽  
Vol 21 (4) ◽  
pp. 187-195 ◽  
Author(s):  
Kathleen C. Romeo Ashton ◽  
Michael S. Saccucci
Keyword(s):  
Gender Differences ◽  
Cardiac Rehabilitation ◽  
Follow Up Study ◽  
And Gender
Sign in / Sign up

Export Citation Format

Share Document